Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**alpha-solanine** is a naturally occurring steroidal glycoalkaloid found in *Solanum* species such as potato and nightshade. It is best known as a plant toxin rather than an approved therapeutic product. In the provided publication context, alpha-solanine was evaluated **in silico** as a potential anti-Alzheimer's agent based on predicted **acetylcholinesterase inhibitory** activity and stronger docking affinity to acetylcholinesterase than rivastigmine in that computational study. However, there is no clear evidence from the provided source that alpha-solanine is an established pharmaceutical drug, clinically developed medicine, or company-sponsored development candidate for Alzheimer disease; its relevance here is primarily as a bioactive natural product and investigational research compound.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on alpha-solanine.